198.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie Inc. $ABBV Shares Acquired by Vanguard Group Inc. - MarketBeat
Sanctuary Advisors LLC Buys 6,911 Shares of AbbVie Inc. $ABBV - MarketBeat
Richard C. Young & CO. LTD. Acquires 6,966 Shares of AbbVie Inc. $ABBV - MarketBeat
Polaris Capital Management LLC Sells 22,167 Shares of AbbVie Inc. $ABBV - MarketBeat
Axecap Investments LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AEGON ASSET MANAGEMENT UK Plc Sells 20,049 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug - Yahoo Finance
Golden Reserve Retirement LLC Invests $1.68 Million in AbbVie Inc. $ABBV - MarketBeat
Calamos Advisors LLC Grows Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Trading Down 1.1%Time to Sell? - MarketBeat
Therapeutics Stocks Q4 Earnings: AbbVie and Novavax Performance Analysis as of April 2026News and Statistics - IndexBox
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie Stock: Skyrizi and Rinvoq Already Cleared 2027 Guidance, But Does the Discount Still Make Sense? - TIKR.com
AbbVie’s move to revitalize Botox demand stymied by FDA questions - Crain's Chicago Business
AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues - Yahoo! Finance Canada
US FDA rejects AbbVie's wrinkle treatment due to manufacturing concerns - Reuters
Biopharma company AbbVie to create 730 jobs in Durham - WRAL
Insights Into AbbVie (ABBV) Q1: Wall Street Projections for Key Metrics - Yahoo Finance
Turtle Creek Wealth Advisors LLC Has $4.74 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug - Benzinga
AbbVie (ABBV) Faces FDA Setback on TrenibotE Approval - GuruFocus
Quent Long Short Global Small Cap Fund LP Invests $2.17 Million in AbbVie Inc. $ABBV - MarketBeat
AbbVie anti-wrinkle therapy rejected at FDA (ABBV:NYSE) - Seeking Alpha
AbbVie Inc. $ABBV Shares Sold by Torray Investment Partners LLC - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Arizona State Retirement System - MarketBeat
AbbVie receives CRL from FDA regarding BLA for trenibotulinumtoxinE - TipRanks
Earnings Preview: AbbVie to Report Financial Results Pre-market on April 29 - Moomoo
AbbVie wrinkle treatment rejected by FDA over manufacturing issues - Investing.com Canada
Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus - BioPharma Dive
AbbVie Gets FDA Complete Response Letter on TrenibotE BLA - marketscreener.com
FDA Requests Additional Information on AbbVie's Application for Neurotoxin - Moomoo
AbbVie Provides Update on TrenibotulinumtoxinE Biologics License Application in the U.S. - Investing News Network
AbbVie (ABBV) Receives Complete Response Letter from FDA on Tren - GuruFocus
US FDA declines to approve AbbVie's wrinkle treatment - marketscreener.com
AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S. - marketscreener.com
Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4 - Yahoo Finance
AbbVie’s aesthetic neurotoxin faces FDA manufacturing questions - Stock Titan
ABBV Maintains Overweight RatingPrice Target Lowered to $294 - GuruFocus
AbbVie Price Target Cut to $294.00/Share From $299.00 by Piper Sandler - Moomoo
AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results? - The Globe and Mail
Piper Sandler lowers Abbvie stock price target on IL-23 competition - Investing.com Canada
OLD National Bancorp IN Reduces Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Stake Boosted by Milestone Asset Management LLC - MarketBeat
AbbVie Announces $1.4B Investment in North Carolina - Contract Pharma
AbbVie to invest $1.4bn in North Carolina manufacturing campus - The Manufacturer
AbbVie price target lowered to $294 from $299 at Piper Sandler - TipRanks
HB Wealth Management LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie to Invest $1.4B in New Pharmaceutical Manufacturing Facility in Durham, North Carolina - REBusinessOnline
AbbVie opts for North Carolina to house $1.4bn manufacturing site - Pharmaceutical Technology
ABBV (AbbVie Inc.) posts narrow Q4 2025 EPS beat, shares dip slightly in daily trading.Earnings Volatility - Cổng thông tin điện tử Tỉnh Sơn La
AbbVie to invest $1.4 billion in NC facility - The Pharma Letter
$1.4Bn AbbVie Manufacturing Campus Announced for Durham, North Carolina - Construction Review
B. Metzler seel. Sohn & Co. AG Purchases 335,055 Shares of AbbVie Inc. $ABBV - MarketBeat
ABBV Stock Price, Quote & Chart | ABBVIE INC (NYSE:ABBV) - ChartMill
AbbVie (ABBV): The Best Stock to Buy on a Pullback - Yahoo Finance
AbbVie becomes 8th of top 10 pharmaceutical manufacturers in North Carolina - The Center Square
Does AbbVie’s Durham AI Plant and Ovarian Cancer Data Reframe the Bull Case for ABBV? - Yahoo Finance
AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development - Insider Monkey
Pharma giant AbbVie plans $1.4 billion campus near Research Triangle Park - Axios
AbbVie Invests $1.4 Billion in New Manufacturing Facility - GuruFocus
ABBV (AbbVie Inc.) edges past Q4 2025 EPS estimates, posts 8.6 percent revenue growth, shares dip 0.88 percent. - Cổng thông tin điện tử tỉnh Lào Cai
AbbVie | Pharmaceutical company to build new campus in North Carolina, bring hundreds of jobs to Durham - ABC11 Raleigh-Durham
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):